The development of specific anti-inflammatory agents for the treatment of asthma is overdue, but new research provides scope for optimism. Two early reports suggest that therapeutic agents blocking ...

In recent years, they’ve proven effective at treating severe asthma. Asthma treatments have ... Anti-eosinophilic antibodies target interleukin-5 (IL-5). This immune system protein activates ...

Dupixent, an interleukin-4 and 13 inhibitor, was approved in Europe in asthma in May last year, following a previous approval in eczema. The type 2 inflammation that this label covers occurs in ...

for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is an ultra-long acting biologic with high binding affinity for interleukin-5 ...

Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented NLRP3 inflammasome and interleukin-1β (IL1B; IL-1β) release inhibitors reported to be useful for the treatment of ...